Kemwell is a leading pharmaceutical contract development and manufacturing company. With headquarters in Bangalore, India, we employ more than 1,000 people across our manufacturing facilities in India and Sweden, catering to five of the top ten pharma companies of the world with packaging and global distribution.
Kemwell is a full-service provider and a 100% customer-oriented company with deep expertise in contract manufacturing and development services for pharmaceutical products globally. Kemwell provides expert solutions in product development, sourcing, analytical support, clinical batch production, and commercial-scale manufacturing and packaging solutions, with distribution from facilities that are certified by USFDA, EU and Japanese regulatory authorities.
The majority of dose forms we offer today, which marry European and Asian strengths, are: solid dose tablets; uncoated, sugar-coated and film-coated (solvent and aqueous) tablets; suppositories; effervescent and bi-layer tablets; hard gelatin capsules filled with powder, granules, pellets or liquid-orals; semi-solid creams, gels and ointments; and controlled and psychotrophic drug substances.
Our common biopharmaceutical facility (15,000m²) for large molecules in Bangalore offers services such as full-service process development, manufacture, formulation, and fill and finish. The cGMP manufacturing facility is a one-stop-shop, with access to large-scale commercial production.
Kemwell has the experience, expertise and infrastructure in place to meet your every need. Discover how our development and manufacturing solutions can keep you competitive. They include:
Whether you are looking for pre-formulation studies, formulation development, stability studies, analytical support, clinical batch production, commercial-scale manufacturing or packaging, Kemwell is the ideal partner for you.
Through collaboration and innovation, Kemwell meets every challenge successfully, refusing to rest until the customer is satisfied.
Our Swedish facilities have over 50 years of experience in supplying pharmaceutical products. Our core process technologies include wet and dry granulation, compaction, blending and high shear mixing, fluid bed drying, tablet pressing, capsule filling, semi-solid moulding, coating and vision inspection.
We also provide QP release services for Europe for products manufactured at our site or outside the EU, thereby covering the full chain of QA responsibility for API and finished products. We have been inspected by USFDA, EU and Japanese regulatory authorities, and supply to over 80 markets worldwide.
Spread over 14,000m², our Swedish facilities are capable of expanding and adapting quickly to meet the high demands of the customer.
Kemwell’s new oral solids facility is a state-of-the-art facility built in Bangalore to manufacture up to five billion tablets and capsules for global supply. Covering over 15,000m², the facility has been designed to marry flexibility with stringent measures for contamination control.
Kemwell’s liquids facility has been supplying to customers since 1995 and has benefited from continuous investments in process improvements and expansions. We are now building a new liquids facility to increase our manufacturing capacity.
Kemwell’s semi-solids facility has been operational since 2001. We manufacture gels, ointments, creams and solutions for various topical and ophthalmic applications.
Kemwell meets cGMPs as per international quality guidelines, which ensures that all products meet the highest quality standards. We continue to invest in people, processes and equipment to ensure that Kemwell remains a quality leader in every aspect of its business and that quality is the foundation of its success.
Our quality policy is: